By Professor Murray David Norris

Conference Posters

Haber M; Karsa M; Connerty P; Karsa A; Spurling D; Pomilio G; Litalien V; Xie J; Cheung LC; Kotecha RS; Chernova O; Gudkov AV; Lock RB; Norris MD; Wei AH; Moujalled D; Somers K, 2026, 'Abstract 3979: Targeting nicotinamide metabolism with NAMPT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemia', Vol. 86, pp. 3979 - 3979, http://dx.doi.org/10.1158/1538-7445.am2026-3979

Karsa M; Connerty P; Karsa A; Spurling D; Pomillio G; Litalien V; Cheung L; Kotecha R; Chernova O; Gudkov A; Lock R; Norris M; Haber M; Wei A; Moujalled D; Somers K, 2025, 'Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models', Vol. 146, pp. 3282, http://dx.doi.org/10.1182/blood-2025-3282

Karsa M; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Somers K; Henderson MJ, 2018, 'PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia', Vol. 3, pp. a181, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431

Back to profile page